Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-02-26FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., expanding/adjusting its approved labeling for the drug.
-
CLINICAL_TRIALS trial_result · 2016-02-23Clinical Trial Update: Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older [Phase 3]
Phase 3 trial comparing lacosamide to carbamazepine-CR as initial monotherapy in epilepsy shows results completed with posted findings in 20…
-
FDA approval · 2016-02-19FDA Approved: MYSOLINE — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for Mysoline (primidone) submitted by Bausch Health US, LLC.
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) based on UCB, Inc.'s original NDA, establishing it as an adjunctive therapy for partial-onset seizures …
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
The FDA approved Briviact (brivaracetam) as an adjunctive treatment for partial-onset seizures in adults and in children aged 4 years and ol…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) under its original application by UCB, Inc. for adjunctive treatment of partial-onset seizures in epile…
-
FDA approval · 2016-02-18FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote ER (divalproex sodium) from AbbVie Inc., granting an additional regulatory authorizatio…
-
FDA label_change · 2016-02-18FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie, resulting in a labeling update for the produ…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures [Phase 4]
A Phase 4 trial compared adjunctive levetiracetam to topiramate in adults with refractory partial-onset seizures. The study is completed and…
-
FDA approval · 2016-02-04FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) from UCB, Inc. The approval updates KEPPRA's labeling to reflect the supp…
-
CLINICAL_TRIALS trial_result · 2016-02-04Clinical Trial Update: Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs [Phase 3]
Phase 3 trial evaluating eslicarbazepine acetate as monotherapy for partial epilepsy not well controlled by current antiepileptic drugs; saf…
-
FDA approval · 2016-02-04FDA Approved: GABAPENTIN — Original Application (Creekwood Pharmaceuticals LLC)
FDA approved Creekwood Pharmaceuticals LLC's gabapentin under an Abbreviated New Drug Application, authorizing the generic product's market …
-
FDA approval · 2016-02-03FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approves a supplemental application for gabapentin from Exelan Pharmaceuticals, Inc., granting regulatory approval for this generic prod…
-
FDA approval · 2016-02-02FDA Approved: LEVETIRACETAM — Supplemental Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved a supplemental application for levetiracetam from Quagen Pharmaceuticals LLC, authorizing the generic product under an ANDA and…
-
FDA approval · 2016-02-01FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Levetiracetam submitted by Prasco Laboratories. The update concerns changes to the product label…
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study [Phase 4]
Phase 4, single-arm, open-label trial in Japanese women with epilepsy evaluating dose reduction of valproate with the addition of lamotrigin…
-
FDA approval · 2016-02-01FDA Approved: LEVETIRACETAM — Original Application (Eugia US LLC)
The FDA approved an Abbreviated New Drug Application (ANDA) for levetiracetam from Eugia US LLC, authorizing the marketing of a generic vers…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures [Phase 3]
Phase 3 trial update evaluating adjunctive perampanel (E2007) for refractory partial seizures in epilepsy; results were posted in 2016.
-
FDA label_change · 2016-01-25FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC, indicating a labeling update for this p…
-
CLINICAL_TRIALS trial_result · 2016-01-25Clinical Trial Update: Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs [NA]
This clinical trial update reports immunological and viral parameter analyses in patients receiving anti-epileptic drugs; the study status i…
-
CLINICAL_TRIALS trial_result · 2016-01-22Clinical Trial Update: Seizure Detection and Automatic Magnet Mode Performance Study [NA]
A completed clinical trial update evaluating seizure detection and automatic magnet mode performance in epilepsy. Results were posted in 201…
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: Determination of Absorption and Elimination of Lamotrigine-XR [Phase 1, Phase 2]
This update reports a Phase 1/2 pharmacokinetic assessment of Lamotrigine-XR to determine its absorption and elimination. Results have been …
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users [Phase 4]
A Phase 4 pilot study evaluating pharmacokinetics and pharmacodynamics of anti-epileptic drugs in women using a levonorgestrel intrauterine …
-
FDA approval · 2016-01-14FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for levetiracetam, enabling the generic version to be marketed.
-
FDA approval · 2016-01-14FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for levetiracetam from Torrent Pharmaceuticals Limited, enabling the marketing of a generic version.